Osteoprotegerin Serum Level is Associated with Severity of Coronary Artery Calcification in Non Diabetic Centrally Obese Men

Trilis Yulianti, Antonia Anna Lukito, Andi Wijaya, Gatot Susilo Lawrence, Syakib Bakri

Abstract


BACKGROUND: Osteoprotegerin (OPG) is produced by a variety of tissues including those of the cardiovascular system. Recent clinical studies have suggested a significant correlation between elevated OPG serum level and cardiovascular mortality. Since coronary artery calcification (CAC) is positively associated with cardiovascular disease (CVD) events, we carried out a study to investigate whether OPG serum level is associated with the severity of CAC in non diabetic centrally obese men.

METHODS: A cross sectional study was done on seventy non diabetic centrally obese men. CAC score was determined by using dual source computed tomography (DSCT). OPG serum level was measured by enzyme-linked immunosorbent assay (ELISA) method. Statistical analysis was done with SPSS for windows ver 16. ANOVA was performed to analyze mean, maximum, minimum value, and standard deviation. Spearman correlation test was performed to determine the correlation between OPG serum level and CAC score. Significance value was defined as alpha level=0.05 based on two-tailed tests.

RESULTS: OPG serum level was significantly correlated with CAC score. The severity of CAC increased with the increase of OPG level. Age was significantly correlated with OPG serum level and CAC score.

CONCLUSIONS: Our data show that serum OPG level was associated with the severity of CAC, which highlights that OPG could be involved in the progression of CAC in non diabetic obese men.

KEYWORDS: obesity, vascular calcification, osteoprotegerin, coronary artery calcification


Full Text:

PDF

References


The National Institute of Health Research and Development, Ministry of Health, Republic of Indonesia. Report on Result of National Basic Health Research (RISKESDAS) 2007. Jakarta: Ministry of Health Republic of Indonesia; 2008, article.

World Health Organization. World Health Organization on Cardiovascular disease. Geneva: WHO; 2012.

Koshiyama H, Ogawa Y, Tanaka K, Tanaka I. The unified of interactions among the bone, adipose and vascular systems: “Osteo-lipo-vascular interactions". Med Hypotheses. 2006; 66: 960-3, CrossRef.

Campenhout AV, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis. 2009; 204: 321-9, CrossRef.

Cao J, Venton L, Sakata T, Halloran BP. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res. 2003; 18: 270-7, CrossRef.

Mazzioti G, Amato G, Sorvillo F, Piscopo M, Rizzo MR, Lalli E, et al. Increased serum osteoprotegerin values in longlived subjects: different effects of inflammation and bone metabolism. EurJ Endocrinol. 2006; 154: 373-7, CrossRef.

Atkinson J. Age related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences. J Appl Physiol. 2008; 105: 1643-51, CrossRef.

Wong ND, Kouwabunpat D, Vo AN, Detrano RC, Eisenberg H, Goel M, et al. Coronary calcium and atherosclerosis by ultrafast computed tomography in asymptomatic men and women: relation to age and risk factors. Am Heart J. 1994; 127: 422-30, CrossRef.

Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12: 1260-8, CrossRef.

Price PA, June HH, Buckley JR, Wiliamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and vitamin D. Arterioscler Thromb Vasc Biol. 2001; 21: 1610-6, CrossRef.

Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr (-/-) mice. Circulation. 2008; 117: 411-20, CrossRef.

Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001; 86: 631-7, CrossRef.

Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004; 109: 2175-80, CrossRef.

Ueland T, Kjekshus J, Froland SS. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol. 2005; 46: 2018-21, CrossRef.

Hjelmesaeth J, Ueland T, Flyvbjerg A, Bollerslev J, Leivestad T, Jenssen T, et al. Early posttransplant serum osteoprotegerin levels predict longterm (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol. 2006; 17: 1746-54, CrossRef.

Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukurst P, et al. Plasma osteoprotegerin levels in the general population L relation to ondices of left ventricular structure and function. Hypertension. 2007; 49: 1392-8, CrossRef.

Fili S, Karalaki M, Schaller B. Mechanisms of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment- related survival factors. Cancer Lett. 2009; 283: 10-9, CrossRef.

Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor-KB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007; 92: 4514-21, CrossRef.

Romas E, Sims NA, Hards DK, Lindsay M, Quinn JWM, Ryan PFJ, et al. Osteoprotegerin reduces osteoclast numbers osteoprotegerin and coronary artery calcification and prevents bone erosion in collageninduced arthritis. Am J Pathol. 2002; 161:1419-27, CrossRef.

Stejskal D, Bartek J, Pastorkova R, Ruzieka V, Oral I, Horalik D. Osteoprotegerin, RANK, RANKL. Biomed Papers. 2001; 145: 61-4, CrossRef.

Sattler A, Schoppet M, Schaefer J, Hofbauer L. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tiss Int. 2004; 74: 103-6, CrossRef.

Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification. Lancet. 2001; 358: 257-9, CrossRef.

Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002; 22: 549-53, CrossRef.

Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL. Calcification of human vascular cells in vitro is correlated with high levels of matrix gla protein and low level of osteopontin expression. Arterioscler Thromb Vasc Biol. 1998; 18: 379-88, CrossRef.

Jono S, lkari Y, Shioi A. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106: 1192-4, CrossRef.

Nitta K, Akiba T, Uchida K. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis. 2003; 42: 303-9, CrossRef.




DOI: https://doi.org/10.18585/inabj.v4i1.158

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute